Literature DB >> 7823387

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials.

K F Schulz1, I Chalmers, R J Hayes, D G Altman.   

Abstract

OBJECTIVE: To determine if inadequate approaches to randomized controlled trial design and execution are associated with evidence of bias in estimating treatment effects.
DESIGN: An observational study in which we assessed the methodological quality of 250 controlled trials from 33 meta-analyses and then analyzed, using multiple logistic regression models, the associations between those assessments and estimated treatment effects. DATA SOURCES: Meta-analyses from the Cochrane Pregnancy and Childbirth Database. MAIN OUTCOME MEASURES: The associations between estimates of treatment effects and inadequate allocation concealment, exclusions after randomization, and lack of double-blinding.
RESULTS: Compared with trials in which authors reported adequately concealed treatment allocation, trials in which concealment was either inadequate or unclear (did not report or incompletely reported a concealment approach) yielded larger estimates of treatment effects (P < .001). Odds ratios were exaggerated by 41% for inadequately concealed trials and by 30% for unclearly concealed trials (adjusted for other aspects of quality). Trials in which participants had been excluded after randomization did not yield larger estimates of effects, but that lack of association may be due to incomplete reporting. Trials that were not double-blind also yielded larger estimates of effects (P = .01), with odds ratios being exaggerated by 17%.
CONCLUSIONS: This study provides empirical evidence that inadequate methodological approaches in controlled trials, particularly those representing poor allocation concealment, are associated with bias. Readers of trial reports should be wary of these pitfalls, and investigators must improve their design, execution, and reporting of trials.

Entities:  

Mesh:

Year:  1995        PMID: 7823387     DOI: 10.1001/jama.273.5.408

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  1479 in total

Review 1.  Nonpharmacologic therapy of osteoarthritis.

Authors:  P J Perkins; M Doherty
Journal:  Curr Rheumatol Rep       Date:  1999-10       Impact factor: 4.592

Review 2.  Which guidelines can we trust?: Assessing strength of evidence behind recommendations for clinical practice.

Authors:  A Liberati; R Buzzetti; R Grilli; N Magrini; S Minozzi
Journal:  West J Med       Date:  2001-04

Review 3.  Understanding controlled trials. Randomisation methods: concealment.

Authors:  D J Torgerson; C Roberts
Journal:  BMJ       Date:  1999-08-07

Review 4.  Systematic review of controlled trials of interventions to promote smoke alarms.

Authors:  C DiGuiseppi; J P Higgins
Journal:  Arch Dis Child       Date:  2000-05       Impact factor: 3.791

5.  Randomized, controlled trials, observational studies, and the hierarchy of research designs.

Authors:  J Concato; N Shah; R I Horwitz
Journal:  N Engl J Med       Date:  2000-06-22       Impact factor: 91.245

6.  Considerations for the design and analysis of experimental studies in physical activity and exercise promotion: advantages of the randomised controlled trial.

Authors:  S S Tai; S Iliffe
Journal:  Br J Sports Med       Date:  2000-06       Impact factor: 13.800

7.  Do patients with osteoarthritis get the clinical research they need?

Authors:  P C Gøtzsche
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

8.  How to assess new treatments.

Authors:  R Slinger; D Moher
Journal:  West J Med       Date:  2001-03

9.  Giving medicine a fair trial. Patients' preferences should be assessed.

Authors:  L Allan; L Tooke
Journal:  BMJ       Date:  2000-12-16

10.  Risks and benefits of preoperative high dose methylprednisolone in surgical patients: a systematic review.

Authors:  S Sauerland; M Nagelschmidt; P Mallmann; E A Neugebauer
Journal:  Drug Saf       Date:  2000-11       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.